Molecular markers and allo-HSCT for AML: the latest developments

被引：0
|
作者：
Esteve, J.
Labopin, M.
Brunet, S.
Pigneux, A.
Brands-Nijenhuis, M.
Schouten, H.
Polge, E.
Gorin, N. -C.
Mohty, M.
机构：
来源：
BONE MARROW TRANSPLANTATION | 2012年 / 47卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S5 / S5
页数：1
相关论文
共 50 条
  • [21] Acceptable Results Of Allo-HSCT From Unrelated Donors In AML Patients Who Failed To Achieve The Complete Remission
    Markiewicz, Miroslaw
    Dzierzak-Mietla, Monika
    Rybicka, Malwina
    Gaj, Magdalena
    Koclega, Anna
    Zielinska, Patrycja
    Bialas, Krzysztof
    Kyrcz-Krzemien, Slawomira
    BLOOD, 2013, 122 (21)
  • [22] Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?
    Wang, Luxiang
    Zhang, Chunli
    Fan, Shuang
    Mo, Xiaodong
    Hu, Xiaoxia
    INNOVATION, 2023, 4 (04):
  • [23] The Prognostic Significance of Wilms' Tumor Gene 1 in Adult AML with Different Risk Stratification Following Allo-HSCT
    Wang, Ke
    Zhou, Songhai
    Sun, Yuqian
    Yan, Chenhua
    Wang, Yu
    Huang, Xiaojun
    Zhao, Xiaosu
    BLOOD, 2020, 136
  • [24] The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries
    Abelsson, J.
    Merup, M.
    Birgegard, G.
    WeisBjerrum, O.
    Brinch, L.
    Brune, M.
    Johansson, P.
    Kauppila, M.
    Lenhoff, S.
    Liljeholm, M.
    Malm, C.
    Remes, K.
    Vindelov, L.
    Andreasson, B.
    BONE MARROW TRANSPLANTATION, 2012, 47 (03) : 380 - 386
  • [25] Acute kidney injury in critically ill allo-HSCT recipients
    Canet, E.
    Lengline, E.
    Zafrani, L.
    Peraldi, M-N
    Socie, G.
    Azoulay, E.
    BONE MARROW TRANSPLANTATION, 2014, 49 (08) : 1121 - 1122
  • [26] The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries
    J Abelsson
    M Merup
    G Birgegård
    O WeisBjerrum
    L Brinch
    M Brune
    P Johansson
    M Kauppila
    S Lenhoff
    M Liljeholm
    C Malm
    K Remes
    L Vindelöv
    B Andréasson
    Bone Marrow Transplantation, 2012, 47 : 380 - 386
  • [27] Mycophenolate mofetil-related diarrhoea in allo-HSCT recipients
    Reactions Weekly, 2023, 1982 (1) : 11 - 11
  • [28] Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases
    Xin, Xiangke
    Zhang, Wenli
    Li, Zhen
    Gui, Ruirui
    Wang, Juan
    Ji, Liyun
    Zhang, Yanli
    Fang, Baijun
    Song, Yongping
    Zu, Yingling
    Zhou, Jian
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [29] The Favorable Results of Allo-HSCT in TKI-Resistant CML
    Markiewicz, Miroslaw
    Dzierzak-Mietla, Monika
    Wisniewska-Piaty, Katarzyna
    Frankiewicz, Andrzej
    Koclega, Anna
    Zielinska, Patrycja
    Wieczorkiewicz-Kabut, Agata
    Sobczyk-Kruszelnicka, Malgorzata
    Bialas, Krzysztof
    Kyrcz-Krzemien, Slawomira
    BLOOD, 2011, 118 (21) : 1772 - 1773
  • [30] THE ROLE OF PPARG EXPRESSION IN PATIENTS WITH AGVHD FOLLOWING ALLO-HSCT
    Wu, X.
    Zhang, J.
    Ma, S.
    Ji, Y.
    Xu, J.
    Xie, Y.
    Han, Y.
    Tang, X.
    Fu, C.
    Wu, D.
    HAEMATOLOGICA, 2017, 102 : 619 - 620
12345